AUTHORS
Kaini Shen, MD, Yi Xu Jr, PhD2, Marco Basset, MD3, Ai Guan, MD4, Claudia Bellofiore, MD5, Chengyang Xu6, Mario Nuvolone Jr, MD, PhD7, Jian Li, MD8, Giovanni Palladini, MD,PhD9, Poalo Milani10
AFFILIATIONS
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, Department of Molecular Medicine, University of Pavia, Pavia, Italy
4 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, Department of Molecular Medicine, University of Pavia, Pavia, Italy
6 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, Department of Molecular Medicine, University of Pavia, Pavia, Italy
8 Center for Rare Diseases, State Key Laboratory of Complex, Severe, and Rare Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
9 Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, Department of Molecular Medicine, University of Pavia, Pavia, Italy
10 Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, Department of Molecular Medicine, University of Pavia, Pavia, Italy
ABSTRACT
Background:
Daratumumab has become a cornerstone of therapy for light-chain (AL) amyloidosis, substantially improving hematologic and organ responses. Unlike multiple myeloma, where continuous or indefinite treatment strategies are commonly adopted, AL amyloidosis has traditionally been treated with fixed-duration regimens. The ongoing EMILIA trial is attempting to define the optimal fixed duration of daratumumab therapy; however, until definitive results become available, the optimal duration of daratumumab maintenance remains unknown.
Methods:
We retrospectively analyzed 399 patients with newly diagnosed AL amyloidosis treated at 2 centers using 2 daratumumab treatment strategies (planned 12 vs planned ≥24 cycles). Baseline characteristics, treatment exposure, discontinuation patterns, and longitudinal outcomes were collected. Using an intention-to-treat approach, overall survival (OS), cumulative incidence of next treatment, and organ responses were compared between groups, with death treated as a competing event in the analysis of cumulative incidence of next treatment.
Results:
The 12- and ≥24-cycle cohorts included 181 and 218 patients, respectively. Compared with the ≥24-cycle cohort, patients assigned to 12 cycles were younger (median age, 60 vs 67 years), had lower bone marrow plasma cell (BMPC) burden (6% vs 18%), higher difference between involved and uninvolved free light chains (dFLC; 410 vs 264 mg/L), and a higher proportion of Mayo stage IIIb disease (26% vs 15%). The median (IQR) number of daratumumab cycles actually administered was 9 (2–12) and 16 (5–24), respectively. Early treatment discontinuation occurred in 54% and 56% of patients (P = 0.571), with comparable distributions of discontinuation reasons (P = 0.409), including achievement of ≥very good partial response (VGPR), inadequate hematologic response, death, and intolerance.
The rates of hematologic response ≥VGPR were similar between the 12-cycle and ≥24-cycle groups (70% vs 67%; P = 0.558). Prolonged daratumumab treatment was associated with improved 24-month renal response ≥VGPR (42% vs 26%; P = 0.023), but did not improve 24-month cardiac responses.
After a median follow-up of 35.5 months (95% CI, 33.7–37.3 months), planned treatment for ≥24 cycles did not improve OS compared with the 12-cycle strategy (P = 0.639). No OS benefit was observed across prespecified subgroups stratified by age (≥65 vs <65 years), BMPC burden (≥10% vs <10%), or Mayo 2004 stage (IIIb vs I–IIIa). Similarly, prolonged daratumumab treatment was not associated with a reduced cumulative incidence of next treatment compared with the 12-cycle strategy (subdistribution hazard ratio 1.29; 95% CI, 0.82–2.05; Gray’s test P = 0.336). Subgroup analyses according to age, sex, BMPC burden, and baseline dFLC level consistently showed no reduction in cumulative incidence of next treatment with prolonged therapy.
Conclusions:
In this multicenter real-world cohort, extending daratumumab maintenance beyond 12 cycles did not improve hematologic response depth, treatment discontinuation patterns, OS, or cumulative incidence of next treatment, despite differences in baseline disease characteristics between treatment strategies. The benefit of prolonged therapy appeared limited to renal response improvement. These findings suggest that the optimal duration of daratumumab maintenance in AL amyloidosis remains uncertain and warrants prospective evaluation.
DISCLOSURES
Kaini Shen, MD: No relevant conflicts of interest to declare.